BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...lung cancer (NSCLC) U.S. $276 Basilea Pharmaceutica Ltd. (SIX:BSLN) / Astellas Pharma Inc. (Tokyo:4503) Cresemba isavuconazole...
BioCentury | Sep 19, 2016
Company News

Basilea, Asahi Kasei Pharma deal

...Basilea granted Asahi exclusive rights in Japan to develop and commercialize isavuconazole. Basilea will receive CHF7...
...trials to treat invasive aspergillosis and mucormycosis. The broad-spectrum water-soluble azole antifungal is marketed as Cresemba...
BioCentury | Sep 19, 2016
Company News

Basilea, Grupo Biotoscana deal

...Basilea granted Grupo Biotoscana exclusive rights to commercialize Cresemba isavuconazole and Zevtera ceftobiprole in 19 Latin...
...million ($11.3 million) up front and is eligible to receive undisclosed regulatory and commercial milestones. Cresemba...
BioCentury | Mar 14, 2016
Company News

Basilea sales and marketing update

...Basilea launched Cresemba isavuconazole in the U.K. and Germany to treat invasive aspergillosis and mucormycosis in...
...IV formulation is EUR688.68 ($753.97) and EUR1,067.39 ($1,168.58) for the tablets. Patients receive 600 mg/day Cresemba...
BioCentury | Jan 11, 2016
Finance

Sowing season

...Hyperuricemia associated with gout U.S. Basilea Pharmaceutica AG (SIX:BSLN) / Astellas Pharma Inc. (Tokyo:4503) Cresemba isavuconazole...
BioCentury | Jan 4, 2016
Finance

Big band swing

...oxidase inhibitor to treat hyperuricemia associated with gout Basilea Pharmaceutica AG (SIX:BSLN) EC approves Cresemba isavuconazonium...
BioCentury | Oct 26, 2015
Clinical News

Cresemba isavuconazonium regulatory update

...The European Commission approved an MAA from Basilea for Cresemba isavuconazonium to treat adults with invasive...
...appropriate. Basilea expects to launch the broad-spectrum water-soluble azole antifungal early next year. Astellas markets Cresemba...
...AG (SIX:BSLN), Basel, Switzerland Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Cresemba isavuconazonium, isavuconazole ( BAL8557...
BioCentury | Oct 17, 2015
Company News

EC approves Basilea's Cresemba

...Basilea Pharmaceutica AG (SIX:BSLN) said the European Commission approved an MAA for Cresemba isavuconazonium to treat...
...launch the broad-spectrum water-soluble azole antifungal early next year. In July, CHMP recommended approval of Cresemba...
...for oral and IV Cresemba to treat aspergillosis and mucormycosis. Astellas holds U.S. rights to Cresemba...
BioCentury | Oct 5, 2015
Finance

Event planner

...Tokyo:4151) Tivozanib Advanced renal cell carcinoma (RCC) Submit MAA YE15 Basilea Pharmaceutica AG (SIX:BSLN) Cresemba isavuconazonium...
BioCentury | Oct 5, 2015
Finance

Drawn and quartered

...IIa study of the therapy Basilea Pharmaceutica AG (SIX:BSLN) / Astellas Pharma Inc. (Toyko:4503) Cresemba isavuconazonium...
Items per page:
1 - 10 of 106